Updated May 2026 | URGENT: Science Day for NAION vision loss cases is June 2, 2026. The FDA issued a warning letter to Novo Nordisk for failing to report serious adverse events — including deaths — on time. There are 3,636 active lawsuits in federal court. No global settlement has been announced yet — which means the window to file with maximum leverage is NOW.
You took Ozempic or Wegovy because a doctor prescribed it. Maybe for type 2 diabetes. Maybe for weight management. Maybe because it was everywhere — in the news, on social media, in every other conversation about health. You trusted that a drug this widely used, this heavily marketed, this carefully regulated would carry adequate warnings about what it could do to your body.
It did not.
As of May 2026, 3,636 people have filed lawsuits in federal court against Novo Nordisk — the manufacturer of Ozempic and Wegovy — and Eli Lilly — the manufacturer of Mounjaro. They allege the companies failed to adequately warn patients and physicians about the drug’s potential to cause gastroparesis (stomach paralysis), intestinal obstruction, and a sudden, often permanent form of vision loss called NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy).
In April 2026, the FDA issued a formal warning letter to Novo Nordisk for failing to report serious adverse events — including patient deaths — on time. That letter is now evidence in thousands of lawsuits.
The litigation is in its critical pre-trial phase. Bellwether trials — the test cases that set the template for how much Novo Nordisk will pay — are expected in late 2026 and 2027. Legal analysts project top-tier settlements of $400,000 to $700,000 for gastroparesis cases and over $1 million for NAION vision loss cases.
If you took Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, or any GLP-1 drug and developed severe gastrointestinal symptoms or sudden vision changes — this guide tells you exactly where the litigation stands, whether you qualify, and what your case may be worth.
What Are GLP-1 Drugs and Why Are They Being Sued?
GLP-1 receptor agonists (glucagon-like peptide-1 drugs) are a class of injectable and oral medications originally developed to treat type 2 diabetes. They work by mimicking a hormone that slows gastric emptying — the rate at which your stomach moves food into the small intestine — and stimulates insulin release. In recent years, their dramatic weight loss effects have made them enormously popular far beyond their original diabetes indication.
The drugs at the center of this litigation:
- Ozempic (semaglutide, injectable) — Novo Nordisk. Approved for type 2 diabetes management.
- Wegovy (semaglutide, injectable, higher dose) — Novo Nordisk. Approved for chronic weight management.
- Rybelsus (semaglutide, oral tablet) — Novo Nordisk. Type 2 diabetes.
- Mounjaro (tirzepatide, injectable) — Eli Lilly. Type 2 diabetes and weight management.
- Zepbound (tirzepatide, injectable) — Eli Lilly. Approved specifically for obesity.
- Trulicity (dulaglutide, injectable) — Sanofi/Eli Lilly.
- Victoza (liraglutide, injectable) — Novo Nordisk.
By 2023, Ozempic and Wegovy had become among the most-prescribed drugs in the United States. Novo Nordisk reported revenues of over $10 billion from semaglutide products. Celebrities and public figures discussed them openly. Supply shortages developed because demand exceeded manufacturing capacity.
And quietly, adverse event reports began accumulating.
What the lawsuits allege:
Novo Nordisk’s own mechanism of action — slowing gastric emptying — carries an inherent risk of severe gastrointestinal dysfunction. Multiple peer-reviewed studies documented this risk. The FDA received thousands of adverse event reports. Yet for years, the drug’s warning label did not tell patients or physicians that Ozempic could cause gastroparesis — the same condition the drug exploits to produce weight loss, now occurring permanently in people who weren’t willing to accept that trade.
The core legal theory is failure to warn: Novo Nordisk and Eli Lilly knew about these risks, had an obligation to disclose them adequately, and chose not to.
The Science Behind the Lawsuits — Verified Research
The gastroparesis evidence:
A 2024 Mayo Clinic study found that long-term semaglutide use was associated with a 3.4-fold increase in gastroparesis diagnoses. This is not a marginal association — it is a tripling of risk in one of the most credible research institutions in the country. The study examined a large patient population and controlled for confounding factors.
GLP-1 drugs work by slowing gastric emptying as part of their mechanism. For most patients using them short-term, this is manageable. For some patients — particularly those using them long-term or at higher doses — the gastric motility effects become pathological and persistent, continuing even after the drug is discontinued.
The vision loss evidence:
A 2024 study published in JAMA Ophthalmology found that semaglutide users were nearly twice as likely to develop NAION compared to non-users. Among diabetic patients, the risk was even higher — 4 times greater than non-users. NAION is a condition in which the optic nerve’s blood supply is disrupted, causing sudden, painless vision loss in one eye that is often permanent. There is no effective treatment once NAION occurs.
The JAMA study was conducted at Harvard Medical School and Massachusetts Eye and Ear. It compared semaglutide users against matched control groups taking other diabetes and obesity medications — isolating the drug’s specific contribution to NAION risk.
The FDA’s response — and its limits:
- September 2023: The FDA added an ileus (intestinal obstruction) warning to Ozempic’s label.
- January 2025: The Ozempic label was updated to state it is “not recommended in patients with severe gastroparesis” — but critically, the label still does not state that Ozempic can cause gastroparesis in patients who didn’t previously have it.
- April 2026: The FDA issued a formal warning letter to Novo Nordisk for failing to report serious adverse events — including deaths — on time.
The label updates confirm that regulators recognize the GI risks. The failure to include a clear causation warning — despite years of adverse event data — is the foundation of the failure-to-warn claims in thousands of lawsuits.
The Two MDLs — Where the Litigation Stands in May 2026
The Ozempic litigation is organized into two separate multidistrict litigations (MDLs), each addressing a different category of injury:
MDL 3094 — Gastroparesis and Gastrointestinal Injuries
Eastern District of Pennsylvania | Judge Karen Spencer Marston
As of May 1, 2026: 3,636 lawsuits pending
MDL 3094 covers plaintiffs who allege they developed gastroparesis, ileus, intestinal obstruction, chronic vomiting, or other severe gastrointestinal complications after taking Ozempic, Wegovy, Mounjaro, Rybelsus, or other GLP-1 drugs.
Current status: The MDL is in the expert discovery phase. Judge Marston has established a framework for case management, including requirements that plaintiffs provide Gastric Emptying Study documentation — a diagnostic test confirming abnormal gastric retention — to proceed with claims. Bellwether trial selection is expected to begin in late 2026. No global settlement has been announced.
The FDA warning letter impact: The April 2026 warning letter to Novo Nordisk for failing to report deaths on time gives MDL 3094 plaintiffs a powerful new piece of evidence — it establishes that Novo Nordisk’s own pharmacovigilance was deficient. That deficiency is directly relevant to the failure-to-warn claims that underlie every lawsuit in the MDL.
MDL 3163 — NAION Vision Loss
Location: New Jersey state multicounty litigation (MCL) + federal proceedings
As of May 2026: 86 federal cases (rapidly growing)
MDL 3163 (and the parallel New Jersey MCL) covers plaintiffs who developed NAION — sudden, often permanent vision loss — after taking semaglutide drugs. A Science Day hearing is scheduled for June 2, 2026, where both sides will present the scientific evidence linking semaglutide to NAION to the presiding judge. Science Days in mass tort litigation are pivotal — they establish which scientific theories will be allowed to proceed to trial and influence how aggressively defendants settle.
The NAION cases are smaller in number but potentially larger in value per claim. Permanent vision loss in one or both eyes affects every aspect of life — driving, working, reading, independence — producing damages calculations that regularly reach or exceed seven figures.
Who Qualifies for an Ozempic or GLP-1 Lawsuit?
Based on the current litigation framework and the eligibility criteria used by leading mass tort law firms, you may qualify if all of the following apply:
You took one of these GLP-1 drugs:
- Ozempic (semaglutide injection)
- Wegovy (semaglutide injection, higher dose)
- Rybelsus (semaglutide oral tablet)
- Mounjaro (tirzepatide injection)
- Zepbound (tirzepatide injection)
- Trulicity (dulaglutide injection)
- Victoza (liraglutide injection)
Off-label use qualifies: You do not need to have been prescribed the drug for its FDA-approved indication. Many patients prescribed Ozempic for weight management rather than diabetes qualify. Off-label prescribing does not affect your eligibility.
And you were diagnosed with one or more of:
Gastroparesis (Stomach Paralysis) Confirmed by a Gastric Emptying Study (GES) showing abnormal retention. Symptoms: severe, persistent nausea and vomiting (typically more than 4 weeks), inability to keep food down, significant unintended weight loss, hospitalization, feeding tube placement, or gastric surgery.
Average GI hospitalization for gastroparesis: $34,585 per hospital stay — evidence that creates clear documentation of economic damages.
Ileus or Intestinal Obstruction Paralysis of bowel function or physical blockage requiring hospitalization, nasogastric tube placement, or surgical intervention.
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) Sudden vision loss or darkening in one eye, typically occurring over hours to days. Often painless. May result in permanent partial or complete vision loss in the affected eye. Documented by ophthalmological examination and visual field testing.
Gallbladder Disease (Cholecystitis / Gallstones) GLP-1 drugs are associated with increased gallstone formation and acute gallbladder inflammation. Cases requiring gallbladder removal (cholecystectomy) qualify in some litigation tracks.
Wrongful Death Families of patients who died from gastroparesis complications, intestinal obstruction, or other GLP-1-linked injuries may file wrongful death claims.
Settlement Values — What the Cases May Be Worth
No global Ozempic settlement has been announced as of May 2026. The litigation is pre-trial, meaning individual case values will be established once bellwether trials begin. Based on expert projections and comparable pharmaceutical mass torts, here is the current value framework:
Gastroparesis — Settlement Tier Projections:
| Tier | Injuries | Projected Settlement |
|---|---|---|
| Tier 1 (Highest) | Permanent severe gastroparesis, feeding tube, multiple hospitalizations, unable to maintain employment | $400,000 – $700,000 |
| Tier 2 | Significant gastroparesis requiring surgery (gallbladder removal, gastric surgery), extended hospitalization | $150,000 – $400,000 |
| Tier 3 | Documented gastroparesis requiring hospitalization, confirmed by GES | $50,000 – $150,000 |
| Tier 4 | Temporary GI symptoms resolving after stopping medication | $10,000 – $50,000 |
NAION Vision Loss — Settlement Tier Projections:
| Category | Condition | Projected Settlement |
|---|---|---|
| Full permanent blindness (both eyes) | Total vision loss | $1,000,000 – $3,000,000+ |
| Significant permanent vision loss (one eye) | Cannot drive, work, or function independently | $500,000 – $1,000,000+ |
| Partial vision loss (one eye) | Reduced visual field, documented NAION | $250,000 – $500,000 |
Why NAION claims are worth more: NAION is irreversible — there is no treatment that restores vision once the optic nerve is damaged. Sudden blindness in working-age patients produces enormous economic damages (lost lifetime earnings) plus non-economic damages for loss of independence, inability to drive, and permanent alteration of daily life. The 2024 JAMA study establishing 2x to 4x increased risk provides strong scientific causation evidence.
Punitive damages potential: The April 2026 FDA warning letter documenting Novo Nordisk’s failure to report adverse events — including deaths — on time creates a pathway for punitive damages. Pharmaceutical companies that conceal or delay reporting safety data face punitive multipliers on compensatory awards. If Novo Nordisk’s internal documents reveal they understood the full extent of GI risks earlier than their label changes reflect, punitive damages could substantially increase total case values.
The Novo Nordisk Failure-to-Warn Case — What the Evidence Shows
The legal core of every Ozempic lawsuit is failure to warn — Novo Nordisk’s obligation under federal law to update Ozempic’s label when new safety data emerges, and their alleged failure to do so adequately.
The timeline that matters:
2012–2019: Adverse event reports of severe gastrointestinal complications begin accumulating in the FDA’s database. Early clinical trial data shows gastric emptying effects. Novo Nordisk’s own pharmacologists understood the mechanism.
September 2023: FDA adds ileus (intestinal obstruction) warning to Ozempic label — 5+ years after initial adverse event signals appeared.
2024: JAMA Ophthalmology study published linking semaglutide to 2x–4x increased NAION risk. The research had been building in the scientific literature since Ozempic’s approval.
January 2025: Ozempic label updated to say the drug is “not recommended” for patients with severe gastroparesis. Critically, the label still does not state that Ozempic can cause gastroparesis in patients who were previously healthy.
April 2026: FDA issues warning letter to Novo Nordisk for failing to report serious adverse events — including deaths — within required timeframes. This is a formal regulatory enforcement action.
The legal significance: Every delay in label updating is a period during which patients took the drug without adequate warning. Every patient who developed gastroparesis or NAION during that period and who would have made a different prescribing decision with better information is a potential plaintiff. The FDA’s own enforcement action validates the argument that Novo Nordisk’s safety reporting was deficient.
The Drugs Novo Nordisk and Eli Lilly Are Defending
Understanding who the defendants are helps explain why this litigation will produce significant settlements:
Novo Nordisk is a Danish pharmaceutical company. Ozempic generated $14.3 billion in revenue in 2023 — making it one of the most commercially successful drugs in pharmaceutical history. Wegovy added billions more. The company’s market capitalization briefly exceeded $500 billion. They have financial resources to both defend and settle this litigation.
Eli Lilly manufactures Mounjaro (tirzepatide) and Zepbound, which work through a similar mechanism and face similar allegations. Lilly’s tirzepatide drugs have also generated billions in revenue.
Companies with these revenue profiles pay settlements in the eight-to-ten-figure range when the liability is established. Bayer paid $11 billion for Roundup. Johnson & Johnson proposed an $8 billion fund for talcum powder. Novo Nordisk’s financial capacity to settle this litigation — and their business incentive to resolve it before trial creates further damaging headlines — is not in question.
What to Do If You Were Injured — The Action Plan
Step 1 — Document your diagnosis immediately
Your case depends on medical documentation of your injury. Ensure the following exist in your medical records:
- Gastric Emptying Study (GES) confirming gastroparesis
- Hospitalization records for gastroparesis, ileus, or obstruction
- Ophthalmological examination records documenting NAION
- Prescription records for Ozempic, Wegovy, or Mounjaro
- Records of when you started and stopped the drug
Step 2 — Stop assuming your case is too minor
Many people who experienced severe vomiting, prolonged nausea, inability to eat, or emergency hospitalization assume their symptoms weren’t serious enough for a lawsuit. If you were hospitalized — even once — with confirmed gastroparesis following GLP-1 drug use, your case has documented economic damages from that hospitalization alone. The $34,585 average gastroparesis hospitalization cost is documented evidence. Get a case evaluation before concluding you don’t qualify.
Step 3 — Contact an Ozempic lawsuit attorney for a free evaluation
Every law firm handling GLP-1 cases works on contingency — zero upfront cost. The evaluation is free. The attorney reviews your prescription history and diagnosis and tells you whether your case meets current eligibility requirements. Most evaluations take 15 to 30 minutes.
Step 4 — File sooner rather than later
No settlement deadline has been set — but mass torts typically impose cutoff dates for claim enrollment once a global settlement framework is established. Filing now places you in the litigation before those cutoffs are imposed. It also preserves your statute of limitations rights, which vary by state and which can expire even while the MDL is pending.
Statute of Limitations — Filing Deadlines by State
GLP-1 drug injury claims are governed by each state’s product liability or personal injury statute of limitations. Most states allow 2 to 4 years from the date of injury discovery — the date when you knew or reasonably should have known that your condition was linked to Ozempic or another GLP-1 drug.
| State | Time Limit | Notes |
|---|---|---|
| California | 2 years from discovery | Discovery rule extends from when injury linked to drug |
| New York | 3 years from injury | Product liability |
| Texas | 2 years | Strict — few exceptions |
| Florida | 4 years | Product liability rule |
| Illinois | 2 years from discovery | Gastroparesis MDL centered in N.D. Illinois |
| Pennsylvania | 2 years | MDL 3094 in E.D. Pennsylvania |
| New Jersey | 2 years | NAION MCL in New Jersey |
| Ohio | 2 years |
The discovery rule is critical: If you were diagnosed with gastroparesis in 2022 but only connected your diagnosis to Ozempic in 2024 when news coverage emerged, your 2-year window may have started in 2024 — not 2022. An attorney can advise on how the discovery rule applies to your specific facts.
Frequently Asked Questions
Can I sue if I took Mounjaro or Wegovy rather than Ozempic? Yes. The litigation covers all GLP-1 receptor agonists, not just the Ozempic brand. Mounjaro (Eli Lilly), Wegovy (Novo Nordisk), Zepbound (Eli Lilly), Trulicity, Rybelsus, and Victoza are all included. The injury mechanism — slowing of gastric emptying, optic nerve blood supply disruption — is similar across the drug class. Your specific drug name determines which defendant your case is filed against, but all qualify for evaluation.
Do I need a Gastric Emptying Study to file? A Gastric Emptying Study (GES) — a diagnostic test in which you eat food mixed with a radioactive tracer and technicians measure how quickly it passes through your stomach — is the gold standard diagnostic confirmation for gastroparesis. Judge Marston has indicated that GES documentation may be required to keep gastroparesis cases in MDL 3094. If you have been diagnosed with gastroparesis but have not had a GES, an attorney can advise on whether your existing documentation is sufficient or whether a GES should be obtained.
What if I took Ozempic off-label for weight loss rather than diabetes? Off-label use doesn’t disqualify you. Many patients prescribed Ozempic for weight management rather than diabetes are eligible plaintiffs. Novo Nordisk’s failure-to-warn obligation applies regardless of whether the prescribing was on-label or off-label — the relevant question is whether the warning label adequately disclosed the risk, not what diagnosis prompted the prescription.
Is there a class action settlement I can join? There is no Ozempic class action settlement as of May 2026. These are individual personal injury lawsuits consolidated for pretrial efficiency in an MDL — not a class action in which all plaintiffs share a single settlement amount. Each plaintiff maintains their own case with their own damages. Your individual settlement amount depends on the specifics of your injury, treatment burden, and medical documentation.
How long will the Ozempic lawsuit take to resolve? Based on comparable pharmaceutical mass torts (Vioxx, Zantac, Xarelto), the likely timeline from current filing to global settlement is 2 to 4 years from the first bellwether trial. Given that bellwether trials are expected in late 2026 or early 2027, meaningful individual settlements could begin as early as 2027 to 2028. Filing now places you in the earliest cohort, which typically benefits most from settlement frameworks that favor early-filed cases.
I had a mild case of nausea and vomiting — do I qualify? Probably not, based on current litigation criteria. Law firms are focusing on severe, documented injuries — confirmed gastroparesis requiring hospitalization, gastric surgery, or feeding tube; documented NAION vision loss; or other serious complications. Transient nausea that resolved after stopping the medication typically does not meet the current threshold. Contact an attorney to evaluate your specific facts — but calibrate expectations to severe, documented injuries for current eligibility.
The Bottom Line: Where This Litigation Is Heading
Ozempic and the GLP-1 class are among the most commercially successful drugs in pharmaceutical history. The revenue generated gives Novo Nordisk and Eli Lilly both the financial capacity to settle massive litigation and the business incentive to resolve it before jury verdicts produce headlines that undermine their core drug franchises.
The pattern of pharmaceutical mass tort litigation is consistent: after bellwether trials establish the damages template, global settlement negotiations accelerate. For Roundup, that process paid $11 billion. For Vioxx, $4.85 billion. For Xarelto, $775 million. Ozempic’s commercial scale — and the severity of injuries in the highest-tier cases — supports the projection of significant individual settlement values once trials begin.
The window to file with maximum leverage is now — before bellwether trials, before settlement frameworks impose enrollment cutoffs, and while your statute of limitations is still open.
Contact a GLP-1 lawsuit attorney for a free case evaluation. The call costs nothing. The evaluation is confidential. And if your case qualifies — it may be one of the most significant financial decisions your family makes this year.
This article is for informational purposes only and does not constitute legal advice. Case eligibility, statute of limitations, and settlement projections vary by individual facts and jurisdiction. Consult a licensed attorney for guidance specific to your situation.
Last updated: May 2026 | Data sourced from MDL 3094 and MDL 3163 federal dockets, DrugWatch, ConsumerNotice, TorHoerman Law, Lawsuit Tracker, FDA adverse event database, and verified scientific literature (JAMA Ophthalmology 2024, Mayo Clinic 2024)